Yunas Idnan, Price Malcolm J, Vigneswaran Kugajeevan, Tobias Aurelio, Devall Adam J, Coomarasamy Arri
School of Medical Sciences, Department of Metabolism and Systems Science, University of Birmingham, Birmingham, UK.
Department of Public Health, Canadian University Dubai, Dubai, United Arab Emirates.
Cochrane Database Syst Rev. 2025 Jun 4;6(6):CD016259. doi: 10.1002/14651858.CD016259.
Postpartum haemorrhage (PPH) is a major cause of maternal mortality worldwide. The combination of accurate diagnosis and effective treatment is necessary to improve outcomes. There is uncertainty about which combination of diagnostic and treatment strategies is most effective.
To assess the comparative effectiveness of various combinations of 'diagnostic and treatment' strategies for PPH in women giving birth, and rank them. To explore the relative effects of various diagnostic strategies, when the treatment strategies are the same or similar. To explore the relative effects of various treatment strategies, when the diagnostic strategies are the same or similar.
We searched CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform to 18 October 2024.
Randomised controlled trials or cluster-randomised trials comparing the effects of different combinations of 'diagnostic and treatment' strategies for PPH were eligible. We included studies of women having vaginal or caesarean birth in any setting.
Critical outcomes were: PPH ≥ 500 mL within 24 hours after birth; additional blood loss of ≥ 500 mL following diagnosis of PPH and within 24 hours after birth; PPH ≥ 1000 mL within 24 hours after birth; need for blood transfusion; use of additional uterotonics, and PPH treatment rate. Important outcomes included maternal death.
We used the Cochrane risk of bias tool (RoB 1).
At least two review authors independently assessed trials for inclusion, trustworthiness, risk of bias, and certainty of the evidence using GRADE. We calculated direct and indirect effect estimates, where possible, for critical and important outcomes. Due to limited data, we were unable to perform pairwise meta-analyses and network meta-analyses for the available combinations, or generate rankings.
We included five trials (10 trial arms, 236,771 women); all included women giving birth vaginally and four had a hospital setting. The combinations of diagnostic and treatment strategies were: visual estimation-based diagnosis plus usual care for treatment; 3-option trigger PPH diagnosis with calibrated drape (1. clinical concern, or 2. blood loss ≥ 300 mL to < 500 mL plus abnormal observations, or 3. blood loss ≥ 500 mL) plus MOTIVE (uterine Massage, Oxytocics, Tranexamic acid, IntraVenous fluids, and Examination and Escalation of care) treatment bundle; 2-option trigger PPH diagnosis with calibrated drape (1. clinical concern, or 2. blood loss ≥ 500 mL) plus MOTIVE treatment bundle; calibrated drape-based diagnosis plus usual care for treatment; gravimetric method-based diagnosis plus usual care for treatment; MaternaWell tray-based diagnosis plus usual care for treatment.
3-option trigger PPH diagnosis plus MOTIVE bundle versus visual estimation-based diagnosis plus usual care (direct evidence; 1 study, 170,956 participants) reduces PPH ≥ 500 mL (RR 0.48, 95% CI 0.39 to 0.58; high-certainty evidence), and PPH ≥ 1000 mL (RR 0.34, 95% CI 0.26 to 0.44; high-certainty). Moderate-certainty evidence suggests it probably makes little or no difference to the need for blood transfusion (RR 0.82, 95% CI 0.62 to 1.08) or additional uterotonics (RR 1.19, 95% CI 0.94 to 1.50), and maternal death (RR 0.73, 95% CI 0.36 to 1.48). 2-option trigger PPH diagnosis plus MOTIVE bundle versus visual estimation-based diagnosis plus usual care (direct evidence; 1 study, 39,176 participants) reduces PPH ≥ 500 mL (RR 0.73, 95% CI 0.60 to 0.89; high-certainty). It probably makes little or no difference to PPH ≥ 1000 mL (RR 0.88, 95% CI 0.69 to 1.12; moderate-certainty), and the need for blood transfusion (RR 1.06, 95% CI 0.55 to 2.04; moderate-certainty), and may make little or no difference to maternal death (RR 1.01, 95% CI 0.00 to 4.0 × 10; low-certainty). High-certainty evidence suggests it increases the need for additional uterotonics (RR 3.54, 95% CI 2.27 to 5.52). 3-option trigger PPH diagnosis plus MOTIVE bundle versus 2-option trigger PPH diagnosis plus MOTIVE bundle (indirect evidence) reduces PPH ≥ 500 mL (RR 0.65, 95% CI 0.49 to 0.86; high-certainty), PPH ≥ 1000 mL (RR 0.38, 95% CI 0.27 to 0.55; high-certainty), and the need for additional uterotonics (RR 0.34, 95% CI 0.20 to 0.55; high-certainty). It probably makes little or no difference to the need for blood transfusion (RR 0.78, 95% CI 0.38 to 1.59; moderate-certainty), and may make little or no difference to maternal death (RR 0.72, 95% CI 0.00 to 2.9 × 10; low-certainty). Calibrated drape-based diagnosis plus usual care (in a European setting (E)) versus visual estimation-based diagnosis plus usual care (E) (direct evidence; 1 study, 25,381 participants) probably makes little or no difference to the need for blood transfusion (RR 0.83, 95% CI 0.57 to 1.21; moderate-certainty). Gravimetric method-based diagnosis plus usual care versus calibrated drape-based diagnosis plus usual care (direct evidence; 1 study, 1195 participants) reduces PPH ≥ 500 mL (RR 0.54, 95% CI 0.32 to 0.90; high-certainty), and may make little or no difference to need for blood transfusion (RR 1.00, 95% CI 0.06 to 15.94; low-certainty). MaternaWell tray-based diagnosis plus usual care versus calibrated drape-based diagnosis plus usual care (direct evidence; 1 study, 63 participants) may make little or no difference to PPH ≥ 500 mL (RR 0.61, 95% CI 0.11 to 3.38; low-certainty), and PPH ≥ 1000 mL (RR 0.30, 95% CI 0.01 to 7.19; low-certainty). Gravimetric method-based diagnosis plus usual care versus MaternaWell tray-based diagnosis plus usual care (indirect evidence) may make little or no difference to PPH ≥ 500 mL (RR 0.89, 95% CI 0.15 to 5.35; low-certainty). No data were available for other critical and important outcomes.
AUTHORS' CONCLUSIONS: Both 3-option trigger PPH diagnosis plus MOTIVE bundle and 2-option trigger PPH diagnosis plus MOTIVE bundle were more effective than visual estimation-based diagnosis plus usual care (direct evidence). 3-option trigger PPH diagnosis plus MOTIVE bundle was more effective than 2-option trigger PPH diagnosis plus MOTIVE bundle (indirect evidence). As the treatment strategy (MOTIVE bundle) is the same in these combinations, the increased effectiveness is likely due to the 3-option trigger PPH diagnosis, which adds blood loss of ≥ 300 mL to < 500 mL in the drape plus abnormal clinical observations as a PPH diagnostic trigger. None of the comparisons demonstrated differences in blood transfusion or maternal mortality outcomes. Future research should assess the effectiveness of combination diagnostic and treatment strategies in non-hospital settings, and for women having a caesarean birth. Studies should provide more data on side effects, and maternal experience of care.
Gates Foundation REGISTRATION: PROSPERO (CRD42024600189).
产后出血(PPH)是全球孕产妇死亡的主要原因。准确诊断与有效治疗相结合对于改善结局至关重要。目前尚不确定哪种诊断和治疗策略的组合最为有效。
评估各种“诊断和治疗”策略组合对分娩女性产后出血的相对有效性,并进行排序。探讨在治疗策略相同或相似时,各种诊断策略的相对效果。探讨在诊断策略相同或相似时,各种治疗策略的相对效果。
我们检索了截至2024年10月18日的Cochrane系统评价数据库(CENTRAL)、医学期刊数据库(MEDLINE)、荷兰医学文摘数据库(Embase)、临床试验注册库(ClinicalTrials.gov)和世界卫生组织国际临床试验注册平台。
比较不同“诊断和治疗”策略组合对产后出血影响的随机对照试验或整群随机对照试验符合要求。我们纳入了在任何环境下进行阴道分娩或剖宫产的女性研究。
关键结局指标为:产后24小时内PPH≥500 mL;诊断PPH后且产后24小时内额外失血≥500 mL;产后24小时内PPH≥1000 mL;输血需求;额外使用宫缩剂情况,以及PPH治疗率。重要结局指标包括孕产妇死亡。
我们使用了Cochrane偏倚风险工具(RoB 1)。
至少两名综述作者独立评估试验是否纳入、可信度、偏倚风险以及使用GRADE评估证据的确定性。我们尽可能计算关键和重要结局的直接和间接效应估计值。由于数据有限,我们无法对可用组合进行成对荟萃分析和网状荟萃分析,也无法生成排名。
我们纳入了五项试验(10个试验组,236,771名女性);所有研究均纳入了阴道分娩的女性,其中四项研究为医院环境。诊断和治疗策略的组合包括:基于目测估计的诊断加常规治疗;使用校准手术单的三选项触发式PPH诊断(1. 临床关注,或2. 失血≥300 mL至<500 mL且伴有异常观察结果,或3. 失血≥500 mL)加MOTIVE(子宫按摩、宫缩剂、氨甲环酸、静脉输液以及检查和强化护理)治疗方案;使用校准手术单的两选项触发式PPH诊断(1. 临床关注,或2. 失血≥500 mL)加MOTIVE治疗方案;基于校准手术单的诊断加常规治疗;基于重量法的诊断加常规治疗;基于MaternaWell托盘的诊断加常规治疗。
三选项触发式PPH诊断加MOTIVE方案与基于目测估计的诊断加常规治疗相比(直接证据;1项研究,170,956名参与者),可降低产后24小时内PPH≥500 mL的发生率(RR 0.48,95%CI 0.39至0.58;高确定性证据),以及产后24小时内PPH≥1000 mL的发生率(RR 0.34,95%CI 0.26至0.44;高确定性)。中等确定性证据表明,其对输血需求(RR 0.82,95%CI 0.62至1.08)或额外使用宫缩剂情况(RR 1.19,95%CI 0.94至1.50)以及孕产妇死亡(RR 0.73,95%CI 0.36至1.48)可能影响很小或无差异。两选项触发式PPH诊断加MOTIVE方案与基于目测估计的诊断加常规治疗相比(直接证据;1项研究,39,176名参与者),可降低产后24小时内PPH≥500 mL的发生率(RR